Entyvio beats Humira in head-to-head ulcerative colitis trial

PharmaTimes | September 27, 2019

Entyvio beats Humira in head-to-head ulcerative colitis trial
Takeda has unveiled further data from the VARSITY study showing the superiority of the gut-selective biologic Entyvio (vedolizumab) to the anti-tumour necrosis factor-alpha (anti-TNFα) biologic Humira (adalimumab) in achieving clinical remission in patients with ulcerative colitis (UC). Results of the trial, published in The New England Journal of Medicine (NEJM), show clinical remission rates in patients with moderately to severely active UC of 31.3% for Entyvio and 22.5% for Humira after 52 weeks' treatment. Entyvio achieved higher percentages of clinical remission at week 52 compared to Humira in both anti-TNFα-naïve patients (34.2% versus 24.3%, respectively) and anti-TNFα-experienced patients with UC (20.3% versus 16.0%, respectively). Also, in the secondary endpoints of the study, treatment with Entyvio was linked with significantly higher percentages of mucosal healing at week 52 compared to patients treated with Humira (39.7% versus. 27.7%). However, Takeda's drug was not found to be superior to in the percentage of patients using oral corticosteroids at baseline who discontinued corticosteroids and were in clinical remission at week 52 (12.6% versus 21.8%).

Spotlight

Shares of pharmaceutical company Hospira (HSP) jumped 35% on Thursday, making it TheStreet's move of the day. The stock soared after drug company Pfizer (PFE) announced plans to acquire the company for about $17 billion, with a valuation of $90 per Hospira share. Hospira specializes in providing injectable drugs, a business Pfizer says is expected to grow to $70 billio

Related News

U.S. FDA allows priority review to new drug application for vericiguat treating chronic heart failure

Merck | July 17, 2020

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for vericiguat, an orally administered soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a worsening heart failure event in patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF), in combination with other heart failure therapies. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action date, of Jan. 20, 2021. Vericiguat is being jointly developed with Bayer AG. “This submission builds on Merck’s commitment to patients with cardiovascular disease and long legacy of advancing cardiovascular research to meet unmet medical needs,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “We look forward to working with the FDA as they review this New Drug Application for vericiguat.”

Read More

PHARMA TECH

FDA Grants Breakthrough Device Designation to Wavegate Corporation's StimuLux

Wavegate Corporation | January 14, 2022

Wavegate Corporation announced that the U.S. Food and Drug Administration has granted Breakthrough Device designation for its StimuLux™ optical reflectometry system for closed-loop adaptive modulation of spinal cord stimulation. The FDA's Breakthrough Device designation is designed to expedite the development and regulatory review of medical devices that are intended to treat serious or life-threatening diseases. To qualify for this designation, preliminary evidence must demonstrate a reasonable expectation that the device will provide improved effectiveness compared to the standard of care. "We are pleased the FDA has granted Breakthrough Device designation for our novel StimuLux™ technology. This underscores the urgent need within our society for more effective treatments of chronic, debilitating pain. We are eager to closely collaborate with the FDA as Wavegate works toward advancing the state of the art." Erich Wolf, MD, PhD, Chief Executive Officer "This designation underscores the urgent need within our society for more effective treatments of chronic, debilitating pain." StimuLux™ is a component of Wavegate Corporation's Ellipse neuromodulation platform which integrates multiple patented technologies which aim to systematically address unmet clinical needs within the neuromodulation industry. About Wavegate Corporation Wavegate Corporation is a privately-held start-up neuromodulation company focused on developing and commercializing a suite of technological innovations including: waveform-independent closed-loop adaptive stimulation, a stimulation paradigm for modulation of both ascending and descending spinal cord pain pathways, new implant geometry for reduced surface contact pressures, rapid lead anchoring, and others.

Read More

Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine

Intravacc | September 08, 2020

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has been awarded a contract with base and options that may total US$9.4 million from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic vaccine against enterovirus D68 (EV D68). EV D68 is a respiratory virus that can cause childhood paralysis, Acute Flaccid Myelitis (AFM). Intravacc will develop an inactivated EV D68 vaccine, based on Intravacc's proprietary Vero cell technology, from early product selection through to Phase I clinical testing.

Read More

Spotlight

Shares of pharmaceutical company Hospira (HSP) jumped 35% on Thursday, making it TheStreet's move of the day. The stock soared after drug company Pfizer (PFE) announced plans to acquire the company for about $17 billion, with a valuation of $90 per Hospira share. Hospira specializes in providing injectable drugs, a business Pfizer says is expected to grow to $70 billio